Evaluation of Human Epidermal Growth Factor Receptor-2 in Iraqi Women with Breast Cancer

Evaluation of Human Epidermal Growth Factor Receptor-2 in Iraqi Women with Breast Cancer

Show other versions (1)

Background:Breast cancer (BC) is the most common malignancy in Iraqi women in the recent years. There are many indicated marker for detection BC and determination the development of the tumor stage, one of the most important marker is human epidermal growth factor receptor-2 (HER2). Objective:To...

Full description

Bibliographic Details
Main Authors:	Hiba Hadi Rashid, Walaa Najm Abood, Nameer Fadhel Gaeb
Format:	Article
Language:	English
Published:	College of medicine/ University of Diyala 2019-06-01
Series:	Diyala Journal of Medicine
Subjects:	Breast cancer, serum HER2, tissue HER-2
Online Access:	https://www.djm.uodiyala.edu.iq/index.php/djm/article/view/251

Similar Items

Evaluation of Human Epidermal Growth Factor Receptor-2 in Iraqi Women with Breast Cancer
by: Hiba Hadi Rashid, et al.
Published: (2019-06-01)

Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer
by: Santiago Terán, et al.
Published: (2023-10-01)

Amplification of HER-2 Gene in Benign and Malignant Breast Lesions in a Sample of Iraqi Women
by: Maysoon Abdul-Ameer Ahmed Al-Salman, et al.
Published: (2018-08-01)

Amplification of HER-2 Gene in Benign and Malignant Breast Lesions in a Sample of Iraqi Women
by: Maysoon Abdul-Ameer Ahmed Al-Salman, et al.
Published: (2018-08-01)

Prognostic value and relapse pattern of HER2‐low in hormone receptor‐positive breast cancer
by: Tong Wei, et al.
Published: (2024-03-01)

Frequency of HER-2 over Expression in the Patients with Breast Cancer after Mastectomy
by: S kargar, et al.
Published: (2013-10-01)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
by: Yuxin Mu, et al.
Published: (2023-12-01)

Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
by: Clara Lam, et al.
Published: (2024-04-01)

A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China
by: Shuling Zhou, et al.
Published: (2023-01-01)

How I treat HER2-low advanced breast cancer
by: Ilana Schlam, et al.
Published: (2023-02-01)

Predictability of the Expression of ER, PR Receptors, HER2 and AgNORs in Breast Carcinoma among Iraqi Women in Thi - Qar Province: Immunohistochemical study
by: Hayfaa Abid Ali, et al.
Published: (2019-04-01)

Predictability of the Expression of ER, PR Receptors, HER2 and AgNORs in Breast Carcinoma among Iraqi Women in Thi - Qar Province: Immunohistochemical study
by: Hayfaa Abid Ali, et al.
Published: (2019-04-01)

Predictability of the Expression of ER, PR Receptors, HER2 and AgNORs in Breast Carcinoma among Iraqi Women in Thi - Qar Province: Immunohistochemical study
by: Hayfaa Abid Ali, et al.
Published: (2019-04-01)

Bone metastases of breast cancer: The influence of hormone receptors and human epidermal growth factor receptor 2
by: Rajković Stanislav, et al.
Published: (2024-01-01)

Survival outcomes for HER2-low breast cancer: Danish national data
by: Michael Sode, et al.
Published: (2024-11-01)

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
by: Simon Peter Gampenrieder, et al.
Published: (2021-12-01)

A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers
by: Fnu Amisha, et al.
Published: (2023-05-01)

Low-level expression of human Epidermal growth Factor Receptor-2 (HER2) in High-Grade Mullerian Tumors: Implications for therapy decision making
by: Evi Abada, et al.
Published: (2023-10-01)

Stable or at least once HER2-low status during neoadjuvant chemotherapy confers survival benefit in patients with breast cancer
by: Yingying Zhao, et al.
Published: (2024-12-01)

Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter]
by: Syahruddin FI, et al.
Published: (2024-04-01)

Sortilin‐related receptor is a druggable therapeutic target in breast cancer
by: Hussein Al‐Akhrass, et al.
Published: (2022-01-01)

Interaction between HER-2 and Hormone Receptors in Breast Cancer
by: Majid Moghadaszadeh, et al.
Published: (2010-12-01)

Interaction between HER-2 and Hormone Receptors in Breast Cancer
by: Majid Moghadaszadeh, et al.
Published: (2010-10-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

A bibliometric analysis of HER2-positive breast cancer: 1987–2024
by: Sherlissa Ali-Thompson, et al.
Published: (2024-05-01)

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas
by: Enrico Berrino, et al.
Published: (2022-08-01)

Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review
by: Junjie Li, et al.
Published: (2019-05-01)

Human epidermal growth factor receptor 2 expression in gastric cancer patients treated with curative intent gastrectomy
by: Min Kyu Kim, et al.
Published: (2017-06-01)

Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes
by: Lu Sun, et al.
Published: (2024-12-01)

Comparison of clinicopathological characteristics, efficacy of neoadjuvant therapy, and prognosis in HER2-low and HER2-ultralow breast cancer
by: Feng Guan, et al.
Published: (2024-09-01)

Comparative Analysis and Future Prospects of Human Epidermal Growth Factor Receptor 2 (HER2) and Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted Antibody-Drug Conjugates in Breast Cancer Treatment
by: Gao X, et al.
Published: (2024-09-01)

Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterations
by: Shuai Yan, et al.
Published: (2024-09-01)

Characterization of hormonal receptors and human epidermal growth factor receptor-2 in tissues of women with breast cancer at Muhimbili National Hospital, Dar es salaam, Tanzania
by: Amos Rodger Mwakigonja, et al.
Published: (2017-11-01)

Analysis of clinicopathological characteristics and prognostic factors of early‐stage human epidermal growth factor receptor 2 (HER2)‐low breast cancer: Compared with HER2‐0 breast cancer
by: Qian Wu, et al.
Published: (2023-10-01)

Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis
by: Lin-Yu Xia, et al.
Published: (2024-04-01)

Analysis of clinical features, genomic landscapes and survival outcomes in HER2-low breast cancer
by: Juan Jin, et al.
Published: (2023-06-01)

Unfavorable Prognostic Impact of HER2 2+/FISH-Negativity in Older Patients with HER2-Negative and High-Risk Breast Cancer
by: Wang H, et al.
Published: (2024-11-01)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
by: Mengyuan Cai, et al.
Published: (2023-07-01)